ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PYXS
TRDA (16) ADCT (36) AKBA (49) INO (24) ⌘ Pro Terminal β†’

Pyxis Oncology Inc. (PYXS) β€” RQD Stock Rating Cockpit

$1.69 -6.63% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.67

Pyxis Oncology Inc. (PYXS) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $202.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PYXS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.69 (-6.63% 1D, market cap $202.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PYXS ranks #887 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PYXS compare to TRDA and ADCT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, TRDA (Entrada Therapeutics Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $199.0M) and ADCT (ADC Therapeutics SA) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $196.6M). Among the 5-stock peer group, PYXS leads on earnings multiple (N/A) while AKBA leads on capital efficiency (85.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PYXS?
β–Ό

Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.67 (-1.38%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (27/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510027
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (6)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.2% Base Target
$6 Bull$1 Base$1 Bear
πŸ“¬ FREE PYXS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PYXS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
πŸ” WHY PYXS SCORES 27/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+7/20 pts (26% of score)

FRED Regime Γ— Technicals: 15% of 52W Range β€’ RSI-14 at 37.4 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
35
Grade E$1.79-1.7% Next Q
Q2 (-2Q)
32
Grade E$1.76+12.5% Next Q
Q3 (-1Q)
30
Grade E$1.98-14.6% Next Q
Current
27
Grade E$1.69-10.3% Hist 90D Ξ±
Trajectory: E (35) β†’ E (27)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PYXS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PYXS currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.58) and Max Pain ($1.77) forces dealer call-delta covering toward $5.83.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PYXSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPYXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
37.430 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE15% OF RANGE
L: $1$1.69H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on PYXS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 82.8% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like PYXS
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PYXS)

  • βœ“Walkthrough of PYXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PYXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.65%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $1.81H $1.81L $1.69C $1.69VOL 897.4K
RES: $5.03SUP: $1.59SMA50: $2.58SMA200: $2.16
$4.33$3.58$2.82$2.06$1.31RES $5.03SUP $1.59$1.692026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PYXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PYXS Butterfly Map β†’ + Track PYXS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PYXS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PYXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PYXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PYXS)

Health Care Rank #887 of 1015 βš”οΈ TRDA vs PYXS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PYXS vs. TRDA, ADCT, AKBA, INO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pyxis Oncology Inc. (PYXS) ranks #887 by composite RQD confidence (27/100, grade E) and #570 by equity capitalization ($202.1M). Within this direct 5-issuer industry benchmark cohort, PYXS leads on earnings valuation at N/A trailing P/E, while AKBA leads on capital efficiency and profitability with 85.0% ROIC and 83.3% gross margin. AKBA currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with PYXS at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PYXS ACTIVE
Pyxis Oncology Inc.
E 27/100 β€” 82.8% -35.0% -6.63% $202.1M Benchmark Subject
TRDA
Entrada Therapeutics Inc.
E 16/100 β€” β€” -35.0% +12.68% $199.0M /trda-vs-pyxs β†’
ADCT
ADC Therapeutics SA
D- 36/100 β€” 92.9% -35.0% +0.65% $196.6M /adct-vs-pyxs β†’
AKBA
Akebia Therapeutics Inc.
D 49/100 β€” 83.3% 85.0% +0.27% $196.3M /akba-vs-pyxs β†’
INO
Inovio Pharmaceuticals Inc.
E 24/100 β€” β€” -35.0% +213.75% $195.4M /ino-vs-pyxs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001782223 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pyxis Oncology Inc. (PYXS) reported GAAP revenue of $13.9M (-14.2% vs. FY2024 revenue of $16.1M , and -94.0% cumulative change since FY2023) , GAAP net income of -$79.6M, operating cash flow of -$63.5M, and free cash flow of -$63.5M (-9.7% YoY). On the balance sheet, PYXS closed FY2025 with $91.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $13.9M -$79.6M -$63.5M -$63.5M $91.5M β€”
FY2024 (FY) 2024-12-31 $16.1M -$77.3M -$57.7M -$57.9M $157.2M β€”
FY2023 (FY) 2023-12-31 $230.1M -$73.8M -$70.7M -$70.7M β€” β€”

3. PYXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PYXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pyxis Oncology Inc. (NASDAQ: PYXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.69 (-6.63% 1D, market cap $202.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PYXS ranks #887 in composite RQD confidence.

How does PYXS compare to TRDA and ADCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PYXS carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 82.8%, and ROIC of -35.0%. By comparison, TRDA (Entrada Therapeutics Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $199.0M) and ADCT (ADC Therapeutics SA) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $196.6M). Among the 5-stock peer group, PYXS leads on earnings multiple (N/A) while AKBA leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PYXS?

Per PYXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782223), Pyxis Oncology Inc. generated $13.9M in revenue (-14.2% YoY), -$79.6M in net income, and -$63.5M in free cash flow against $91.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PYXS trading relative to its 50-day, 200-day, and 52-week technical levels?

PYXS last traded at $1.69 (-6.63% on volume of 897,384 shares), positioning the stock -34.50% below its 50-day simple moving average ($2.58) and -21.76% below its 200-day simple moving average ($2.16). Across its 52-week range of $1.03 to $5.55, PYXS sits at the 14.6% percentile with a 14-day RSI of 37.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.48 to $1.90).

Direct Sub-Reports: PYXS RQD Cockpit PYXS 12M Forecast PYXS Earnings & Move PYXS Dividends & DRIP PYXS Insiders & 13F PYXS Whale Options PYXS Profit Sankey PYXS News & Why
ROARABLE RATING BRIEF β€’ RQD 27/100 (E) βœ“ SEC XBRL & RQD VERIFIED

PYXS β€” Pyxis Oncology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pyxis Oncology Inc. (PYXS) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.69 (-6.63% 1D, market capitalization $202.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 82.8%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pyxis Oncology Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B. Per the market data, its gross margin is 82.8%, while operating and net margins are each -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pyxis Oncology Inc. (PYXS) reported $13.9M in annual revenue (up from $16.1M in FY2024, -14.2% YoY) and -$79.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($230.1M revenue, -$73.8M net income) through FY2025, PYXS scaled operating cash flow to -$63.5M and free cash flow to -$63.5M, backed by $91.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.03 – $5.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies are mapped. Sector correlations, 2nd-order bottlenecks, and ripple effects are β€” The only sector context provided is the Health Care / Biotechnology classification and a beta of 1.0.

  • Key Question #1: Can PYXS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $13.9M and free cash flow of -$63.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PYXS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PYXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pyxis Oncology Inc. (PYXS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PYXS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PYXS Bull vs. Bear Conversation Board β€” What's Your Call at $1.69?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PYXS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PYXS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $2.19 (+21.0%)
πŸ“Œ Pinned Debate

The Seeking Alpha item tagged as a CATALYST with a GREEN light points to a runway-focused R&D argument that could support the stock.

The Seeking Alpha item tagged as a CATALYST with a GREEN light points to a runway-focused R&D argument that could support the stock.. When you look under the hood at PYXS, Fundamental Cash Engine is 6/20 with 82.8% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.55. My 12M target is $2.19.

SectorRotator πŸ‚ BULL

@MidwestValue Agree on the RQD 27/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.81 and keeping dry powder in case we test $1.68.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.43 (-21.0%)
Spot @ $1.81

Negative ROIC of -35%, zero FCF yield, and FY 2025 free cash flow of -$63.5M show the business is not generating cash for owners.

Here is the bear case nobody on the bull side wants to address on PYXS: Negative ROIC of -35%, zero FCF yield, and FY 2025 free cash flow of -$63.5M show the business is not generating cash for owners.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE